SEARCH

SEARCH BY CITATION

References

  • 1
    Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension From REVEAL. Chest 2012; 141: 35462.
  • 2
    Benza RL, Miller DP, Gomberg-Maitland M et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 16472.
  • 3
    Humbert M, Sitbon O, Chaouat A et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 15663.
  • 4
    Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 8597.
  • 5
    Hillege HL, Nitsch D, Pfeffer MA et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 6718.
  • 6
    Lin CY, Kao KC, Tian YC et al. Outcome scoring systems for acute respiratory distress syndrome. Shock 2010; 34: 3527.
  • 7
    Enriquez JR, Parikh SV, Selzer F et al. Increased adverse events after percutaneous coronary intervention in patients with COPD: insights from the National Heart, Lung, and Blood Institute dynamic registry. Chest 2011; 140: 60410.
  • 8
    Pabst S, Hammerstingl C, Hundt F et al. Pulmonary hypertension in patients with chronic kidney disease on dialysis and without dialysis: results of the PEPPER-study. PLoS ONE 2012; 7: e35310.
  • 9
    Shah SJ, Thenappan T, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension. Circulation 2008; 117: 247583.
  • 10
    Ronco C, Cruz D, Noland BW. Neutrophil gelatinase-associated lipocalin curve and neutrophil gelatinase-associated lipocalin extended-range assay: a new biomarker approach in the early diagnosis of acute kidney injury and cardio-renal syndrome. Semin Nephrol 2012; 32: 1218.
  • 11
    Damman K, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL. Urinary neutrophil gelatinase associated lipocalin (NGAL), a marker of tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail 2008; 10: 9971000.
  • 12
    Maisel AS, Mueller C, Fitzgerald R et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 2011; 13: 84651.
  • 13
    Koca F, Tanboga IH, Can MM et al. Neutrophil gelatinase-associated lipocalin levels in right and left heart failure: an observational study. Anadolu Kardiyol Derg 2011; 11: 498503.
  • 14
    Seiler S, Cremers B, Rebling NM et al. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J 2011; 32: 268896.
  • 15
    Ix JH, Katz R, Kestenbaum BR et al. Fibroblast Growth Factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 2012; 60: 2007.
  • 16
    Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Investig 2011; 121: 4393408.
  • 17
    Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003; 17: 2393403.
  • 18
    Nabeshima Y. The discovery of alpha-Klotho and FGF23 unveiled new insight into calcium and phosphate homeostasis. CMLS 2008; 65: 321830.
  • 19
    Bernheim J, Benchetrit S. The potential roles of FGF23 and Klotho in the prognosis of renal and cardiovascular diseases. Nephrol Dial Transplant 2011; 26: 24338.
  • 20
    Shimamura Y, Hamada K, Inoue K et al. Serum levels of soluble secreted alpha-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. Clin Exp Nephrol 2012; 16: 7229.
  • 21
    Semba RD, Cappola AR, Sun K et al. Plasma klotho and cardiovascular disease in adults. J Am Geriatr Soc 2011; 59: 1596601.
  • 22
    K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1266.
  • 23
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3141.
  • 24
    Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 60412.
  • 25
    Uno H, Cai T, Pencina MJ, D'Agostino RB, Wei LJ. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med 2011; 30: 110517.
  • 26
    Li G, Xu YL, Ling F et al. Angiotensin-converting enzyme 2 activation protects against pulmonary arterial hypertension through improving early endothelial function and mediating cytokines levels. Chin Med J 2012; 125: 13818.
  • 27
    de Man FS, Tu L, Handoko ML et al. Dysregulated Renin-Angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186: 7809.
  • 28
    Matsushita K, Mahmoodi BK, Woodward M et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 2012; 307: 194151.
  • 29
    Klahr S, Levey AS, Beck GJ et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. New Engl J Med 1994; 330: 87784.
  • 30
    Hsu CY, Propert K, Xie D et al. Measured GFR does not outperform estimated GFR in predicting CKD-related complications. JASN 2011; 22: 19317.
  • 31
    Tangri N, Inker LA, Tighiouart H et al. Filtration markers may have prognostic value independent of glomerular filtration rate. JASN 2012; 23: 3519.
  • 32
    Mielniczuk LM, Chandy G, Stewart D et al. Worsening renal function and prognosis in pulmonary hypertension patients hospitalized for right heart failure. Congest Heart Fail 2012; 18: 1517.
  • 33
    Forfia PR, Mathai SC, Fisher MR et al. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 177: 13649.
  • 34
    Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S. Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol 2006; 26: 28792.
  • 35
    Seiler S, Heine GH, Fliser D. Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int Suppl 2009; S3442.
  • 36
    Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010; 25: 39839.
  • 37
    Plischke M, Neuhold S, Adlbrecht C et al. Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure. Eur J Clin Invest 2012; 42: 64956.